Want to see IRTC full AI Analyst Report?
Top Page
Irhythm Technologies
(NASDAQ:IRTC)
Select Model
Select Model
Rating:62Neutral
Price Target:
$136.00
▲(24.54% Upside)
Action:Reiterated
Date:08/07/26
IRTC’s score reflects improving fundamentals but still-elevated risk: financial performance is recovering with positive EBITDA/operating cash flow, yet leverage remains high and GAAP profitability is not firmly established. The latest earnings call was a major positive driver due to raised guidance, strong Q2 execution, and solid liquidity, while technicals are supportive with strong momentum (though slightly overheated). Valuation remains a headwind given the negative P/E and no dividend yield support.
Positive Factors
High Gross Margin & Product Economics
Sustained ~70%+ gross margins reflect a high-value device plus cloud analytics model and recurring per-episode revenue. Durable product economics provide room for reinvestment and margin expansion as volume scales, supporting long-term cash generation and competitive pricing flexibility.
Negative Factors
High Financial Leverage
A debt-heavy capital structure (nearly 4x D/E) constrains financial flexibility and increases sensitivity to revenue or margin shocks. Higher interest and principal obligations may limit strategic investments, raise refinancing risk, and reduce resilience to cyclical payer or reimbursement changes.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin & Product Economics
Sustained ~70%+ gross margins reflect a high-value device plus cloud analytics model and recurring per-episode revenue. Durable product economics provide room for reinvestment and margin expansion as volume scales, supporting long-term cash generation and competitive pricing flexibility.
Read all positive factors
Irhythm Technologies Key Performance Indicators (KPIs)
Irhythm Technologies (IRTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.06B
Dividend YieldN/A
Average Volume (3M)551.13K
Price to Earnings (P/E)―
Beta (1Y)0.73
Revenue Growth25.58%
EPS Growth85.38%
CountryUS
Employees2,400
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.43
Shares Outstanding32,963,000
10 Day Avg. Volume441,722
30 Day Avg. Volume551,129
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)37.18
Price to Sales (P/S)7.60
P/FCF Ratio164.50
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$174.78Price Target Upside60.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.19
Revenue Forecast (FY)$886.44M
Irhythm Technologies Business Overview & Revenue Model
Company Description
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio s...
How the Company Makes Money
iRhythm primarily makes money by providing ambulatory ECG monitoring services using its Zio wearable devices and associated diagnostic reporting. In typical use, a clinician prescribes a Zio monitor for a patient; the patient wears the device for ...
Irhythm Technologies Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational and financial momentum: high‑teens to low‑20% organic revenue growth, record profitability and free cash flow, raised guidance, constructive reimbursement news, and a strategic acquisition (VitalConnect) that expands modality, market opportunity and multivital capabilities. Notable risks discussed include an outstanding FDA warning letter, a recent cybersecurity incident, a $50 million litigation settlement, integration and regulatory review risks related to the VitalConnect acquisition, and the pending clearance of the company’s Zio MCT product. On balance, positive execution, margin expansion, and clear strategic rationale for the acquisition outweigh the manageable regulatory and integration headwinds.Positive Updates
Strong Revenue Growth
Second quarter revenue of $224.2 million, up 20.1% year‑over‑year; the company reported its seventh consecutive quarter of revenue growth above 20%.
Negative Updates
Outstanding FDA Warning Letter
Company remains subject to an FDA warning letter; while remediation activities and a third‑party audit are completed and submitted, timing for agency action and closure remains uncertain and continues to represent regulatory risk.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Revenue Growth
Second quarter revenue of $224.2 million, up 20.1% year‑over‑year; the company reported its seventh consecutive quarter of revenue growth above 20%.
Read all positive updates
Company Guidance
Management raised full‑year 2026 revenue guidance to $880–$890 million (up 18–19% year‑over‑year) and expects Q3 revenue of $221–$223 million; they raised full‑year adjusted EBITDA margin guidance to 13–14% (Q3 guide 12–13%) and reiterated a combined‑company adjusted EBITDA margin target of 15% for 2027. They expect gross margin to remain above 70% (Q2 gross margin was 72.8%, +160 bps YoY) and noted Q2 results of $224.2 million revenue (+20.1% YoY), $43.3 million adjusted EBITDA (19.3% of revenue), adjusted net income of $19.3 million ($0.58/diluted share), GAAP net loss of $0.4 million ($0.01), record Q2 free cash flow of $37.5 million, and $591.3 million in cash and marketable securities. The announced VitalConnect deal (about a $65 million revenue run‑rate) is excluded from 2026 guidance but is expected to contribute positively beginning in 2027, and management highlighted that a next‑generation FDA‑cleared algorithm (launch H1 2027) could cut technician review time by up to 50% and deliver roughly $100 million of cumulative cost savings over five years.Irhythm Technologies Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
32
Negative
Cash Flow
49
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 825.34M | 747.14M | 591.84M | 492.68M | 410.92M | 322.82M |
| Gross Profit | 589.74M | 527.25M | 407.53M | 331.81M | 281.63M | 213.57M |
| EBITDA | 20.10M | -3.96M | -74.13M | -96.86M | -92.14M | -83.23M |
| Net Income | -13.95M | -44.55M | -113.29M | -123.41M | -116.16M | -101.36M |
Balance Sheet | ||||||
| Total Assets | 1.09B | 1.02B | 931.45M | 433.14M | 448.22M | 462.97M |
| Cash, Cash Equivalents and Short-Term Investments | 591.27M | 583.76M | 535.55M | 133.76M | 213.14M | 239.13M |
| Total Debt | 727.35M | 731.18M | 736.91M | 129.82M | 131.04M | 117.71M |
| Total Liabilities | 906.92M | 867.30M | 840.54M | 223.05M | 208.41M | 183.45M |
| Stockholders Equity | 185.98M | 152.75M | 90.91M | 210.10M | 239.81M | 279.51M |
Cash Flow | ||||||
| Free Cash Flow | 38.98M | 34.52M | -45.55M | -90.53M | -52.84M | -65.82M |
| Operating Cash Flow | 86.00M | 80.86M | 3.39M | -50.10M | -23.01M | -37.75M |
| Investing Cash Flow | -156.43M | -277.06M | -122.98M | -1.21M | -52.43M | 105.26M |
| Financing Cash Flow | 8.01M | 12.61M | 511.38M | 8.82M | 26.72M | -28.58M |
Irhythm Technologies Technical Analysis
Neutral
109.20
Price Trends
116.02
Positive
117.30
Positive
139.24
Negative
Market Momentum
2.70
Negative
54.31
Neutral
32.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRTC, the sentiment is Neutral. The current price of 109.2 is below the 20-day moving average (MA) of 118.49, below the 50-day MA of 116.02, and below the 200-day MA of 139.24, indicating a neutral trend. The MACD of 2.70 indicates Negative momentum. The RSI at 54.31 is Neutral, neither overbought nor oversold. The STOCH value of 32.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IRTC.
Irhythm Technologies Risk Analysis
Irhythm Technologies disclosed 60 risk factors in its most recent earnings report. Irhythm Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Irhythm Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $1.68B | 12.25 | 17.62% | ― | 4.35% | 161.83% | |
71 Outperform | $1.17B | 17.75 | 28.39% | ― | 3.14% | ― | |
69 Neutral | $4.53B | 23.83 | 15.41% | ― | 12.39% | ― | |
68 Neutral | $2.58B | -72.21 | -17.88% | ― | 23.57% | -543.50% | |
64 Neutral | $4.25B | 33.95 | 7.43% | ― | 2.62% | 53.15% | |
62 Neutral | $4.06B | -294.05 | -8.97% | ― | 25.58% | 85.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IRTC
Irhythm Technologies
126.44
-34.14
-21.26%
ITGR
Integer Holdings
125.26
18.47
17.30%
AXGN
AxoGen
48.73
33.80
226.39%
LIVN
LivaNova
82.22
28.50
53.05%
INSP
Inspire Medical Systems
57.10
-30.67
-34.94%
BVS
Bioventus
14.26
6.89
93.49%
Irhythm Technologies Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
Irhythm Technologies Announces Acquisition of Vital Connect
Positive
Aug 6, 2026
On August 5, 2026, iRhythm entered into a definitive agreement to acquire Vital Connect through a merger in which Vital Connect will become a direct wholly owned subsidiary of iRhythm Technologies and an indirect wholly owned subsidiary of iRhythm...
Business Operations and StrategyFinancial DisclosuresLegal ProceedingsM&A Transactions
Irhythm Technologies Boosts Outlook, Expands Cardiac Monitoring Platform
Positive
Aug 6, 2026
On July 31, 2026, iRhythm Technologies, a subsidiary of iRhythm Holdings, reached a settlement with Baxter-related entities to resolve mutual patent litigation over cardiac monitoring sensor technology, agreeing to pay $50 million and granting eac...
Financial DisclosuresLegal Proceedings
iRhythm Technologies Reaches $45 Million Securities Class Settlement
Negative
Jun 5, 2026
On June 3, 2026, iRhythm Tech entered into a binding settlement agreement to resolve a previously disclosed putative securities class action in the U.S. District Court for the Northern District of California, involving the company and CEO Quentin ...
Executive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
iRhythm Technologies Shareholders Approve Governance and Incentive Plan
Positive
May 28, 2026
At its annual meeting on May 27, 2026, iRhythm Technologies, Inc. reported that holders of approximately 89.69% of its common stock were represented, establishing a quorum for conducting business. Stockholders elected nine directors, including C. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.